Retatrutide (Triple Agonist)

Description

Retatrutide for Sale — Research-Grade Triple Agonist

Retatrutide (LY3437943) is a single-molecule triple agonist that activates the GLP-1, GIP and glucagon receptors simultaneously, with balanced potency at each.

Mechanism: The combined incretin (GLP-1 + GIP) and glucagon receptor activity drives appetite suppression, enhanced insulin secretion and elevated resting energy expenditure – a mechanistic combination not present in dual-agonist peptides.

Research findings: The TRIUMPH-1 phase 2 trial reported mean weight reductions of 24.2% at 48 weeks in adults with obesity at the 12 mg dose – the highest weight loss observed in this peptide class. Hepatic fat reductions exceeded 80% in NAFLD sub-analyses.

Handling: Lyophilized peptide. Store sealed at -20°C for long-term stability or 2-8°C short-term. Reconstitute with bacteriostatic water or 0.6% acetic acid as appropriate to the molecule.

For research purposes only. Not for human consumption. This material is intended exclusively for in-vitro laboratory and preclinical research applications conducted by qualified personnel.

Is VMAX retatrutide third-party tested?

Yes our retatrutide is third party tested in the USA

✓
Lab Verified > 99% purity · View lab results →

How should retatrutide be stored?

Store the lyophilized peptide sealed at -20°C for long-term stability, or 2–8°C short-term. After reconstitution, store at 2–8°C and avoid repeated freeze-thaw cycles.

What is the purity of this retatrutide?

Retatrutide is supplied as a lyophilized research compound verified to ≥99% purity by HPLC and mass spectrometry.

Is this retatrutide for human use?

No. This material is sold strictly for in-vitro laboratory and preclinical research by qualified personnel. It is not for human or veterinary use.

What vial sizes are available?

Retatrutide is available in multiple vial sizes — select your preferred option on this product page.